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Case report of ablative magnetic resonance-guided stereotactic
body radiation therapy for oligometastatic mesenteric lymph
nodes from bladder cancer
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Abstract: Several randomized trials have demonstrated that stereotactic body radiation therapy (SBRT)
can significantly improve long-term clinical outcomes for patients with oligometastatic (OM) cancer,
commonly defined as 1–5 metastatic lesions. Some lesions, especially those in the abdomen and pelvis, may
not be appropriate candidates for receiving ablative dose if daily on-board computed tomography (CT)
is used because of limited target lesion and normal anatomy visualization. Magnetic resonance imaging
(MRI) inherently provides superior soft tissue delineation as compared to CT and only recently have MRguided linear accelerators (LINACs) become commercially available. MR-LINACs can also perform daily
online adaptive replanning based on the current day’s anatomy, further positioning this novel technology
as a preferred means to safely deliver ablative dose, even to targets in anatomically challenging locations.
Here we present the case of a 49-year-old man with bladder cancer who underwent cystectomy and
developed metachronous disease in 2 mesenteric lymph nodes for which he received MR-guided SBRT with
daily online adaptive replanning to a prescription dose of 50 Gy in 5 fractions. He achieved a significant
radiographic response and did not experience significant treatment-related toxicity. We discuss unique
advantages of MR guidance and novel applications, especially in the context of OM disease.
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Introduction
Stereotactic body radiation therapy (SBRT) is established
for the management of certain extracranial cancers, most
notably those in the lung, in which ablative dose can safely
be delivered and achieve excellent long-term local control
(LC) (1). SBRT is not feasible for all extracranial tumors,
however, because of suboptimal soft tissue visualization
on pre-treatment computerized tomography (CT) and the
proximity of normal organs such as the bowel.
Daily image guidance using magnetic resonance (MR)
has been available for several years at a limited although
growing number of centers worldwide (2). MR-guided
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radiation therapy (MRgRT) offers several important
advantages over CT-based image guidance that allows for
safe tumor dose escalation while also better sparing normal
organs, and thus may achieve a more favorable therapeutic
ratio.
We present the following case in accordance with the
CARE reporting checklist (available at http://dx.doi.
org/10.21037/tro-20-37).
Case report
This is the case of a 49-year-old man with no significant
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past medical or surgical history who in January 2015
developed hematuria and underwent a workup including
cystoscopy and CT scans that revealed a mass in the bladder
with enlarged pelvic lymph nodes. Bladder biopsy was
positive for invasive high-grade urothelial carcinoma. He
underwent open radical cystectomy and prostatectomy with
bilateral pelvic lymph node dissection and ileal neobladder
urinary diversion in February 2015 for a 4.3 cm, pT3bN2,
invasive high-grade urothelial carcinoma of the bladder
with 2 involved lymph nodes out of 12. Surgical margins
were negative.
Restaging CT scans several years later in May 2017
revealed a 3.7 cm × 2.1 cm right adrenal mass inseparable
from the right diaphragmatic crus that was consistent
with distant metastasis. There was no evidence of disease
recurrence at the primary site of disease in the pelvis or
elsewhere.
He initiated treatment with cisplatin and gemcitabine
in June 2017 for this metachronous OM lesion. CT scans
in August 2017 showed that although the right adrenal
mass was stable two lymph nodes in the central root of the
mesentery were enlarging and suspicious for metastatic
disease. After receiving 7 cycles of cisplatin and gemcitabine,
CT scans in April 2018 showed that the right adrenal mass
had increased to 3.4 cm and the mesenteric lymph nodes
had increased to 3.1 cm and 1.6 cm, respectively. There
were no new lesions elsewhere. Cisplatin and gemcitabine
were discontinued and he was started on atezolizumab.
He began the first cycle of atezolizumab in May 2018
and CT scans approximately 6 months later demonstrated
complete resolution of the right adrenal metastasis while the
mesenteric lymph nodes were stable. His disease remained
well controlled for an additional year until there was again
enlargement of the mesenteric lymph nodes to 5.9 and
1.6 cm, respectively, after 22 cycles of atezolizumab. There
were no additional sites of progression.
Because the mesenteric lymph nodes were the only site
of metastatic disease for an extended period of time the
multidisciplinary tumor board recommended ablative MRguided SBRT, which was delivered in late August 2019 on
the ViewRay MRIdian Linac (ViewRay, Inc., Oakwood
Village, OH). The MRIdian Linac utilizes an onboard
0.35 T MR scanner and step-and-shoot radiation delivery.
Simulation and pre-treatment MRI scans were obtained
on the treatment machine using a True Fast Imaging with
Steady State Free Precession (TRUFISP) sequence without
contrast. An isotropic 3 mm setup margin was placed on the
gross tumor volume (GTV) to define the planning target
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volume (PTV). Elective nodal regions were not treated
given the small bowel surrounding the GTV. The GTV
was 92.9 cc while the PTV was 131.2 cc. Because treatment
was delivered using a coached mid-inspiration breath hold
technique, there was no internal target volume (ITV). The
prescription dose was 50 Gy in 5 consecutive fractions;
the biologically equivalent dose (BED10) was 100 Gy. An
intentional hotspot of at least 120% of the prescription
dose was delivered to as much of the GTV as possible
while respecting normal organ constraints that included
the following: small bowel (V35 <0.5 cc; V40 <0.03 cc),
large bowel (V38 <0.5 cc; V43 <0.03 cc), combined
kidneys (mean <10 Gy), liver (mean <10 Gy), cauda equina
(V20 <0.5 cc). A 3 mm planning organ at risk (PRV) margin
was uniformly expanded around the small bowel and used
as an optimization structure, with the priority being to meet
the normal organ constraints and the secondary goal being
to maximize target volume coverage by the prescription
dose. The prescription isodose line covered 72.6% of the
PTV and 83.4% of the GTV. The mean and maximum
dose to the GTV was 53.6 and 68.6 Gy, respectively. The
treatment plan used 13 inversely optimized beams with a
total of 38 segments.
On each treatment day a volumetric MR TRUFISP scan
was acquired in breath hold over 25 seconds (17 seconds is
another option on the MRIdian Linac). Rigid registration
of the target volumes and deformable registration of the
normal organs was performed. The contours were then
modified to reflect the current day’s anatomy; the normal
organs were recontoured within 3 cm from the periphery
of the PTV. The predicted target volume and normal
organ doses using the current day’s anatomy and original
treatment plan were evaluated. For each of the 5 fractions
the predicted small bowel constraint was violated so the
original plan (Figure 1A) was not used, but rather each
fraction was reoptimized (Figure 1B,C,D,E,F) while the
patient remained in treatment position and treatment was
delivered using the new plan. This allowed all normal
organ constraints to be satisfied while providing excellent
dose coverage of the targeted lymph nodes. Continuous
intrafraction motion was assessed in the sagittal plane
throughout treatment delivery at a rate of 4 frames per
second. Treatment was automatically paused if the at least
5% of the target position extended outside of a 3 mm
threshold boundary; treatment resumed automatically when
the target returned to within the defined threshold. The
median time across all 5 fractions from the patient entering
the treatment room to treatment delivery completion was
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Figure 1 Isodose lines from the original treatment plan (A) compared to each daily fraction (B-F) that underwent online adaptive replanning
due to a significant interfraction change in bowel positioning. The adapted plans ensured all normal organ dose constraints were met; target
coverage varied depending on the current day’s anatomy although most of the target received the prescribed dose for each fraction.

65 minutes, including time for initial positioning and online
adaptive replanning. The median treatment delivery time in
breath hold was 16 minutes.
The patient tolerated treatment very well and was able
to complete MR-guided SBRT within 5 consecutive days
as intended. He did not have severe toxicity and only
experienced mild diarrhea and bloating.
CT scans in September 2019 demonstrated a reduction in
the size of the treated mesenteric lesions to 2.3 and 1.2 cm,
respectively (Figure 2A,B). Two months later there was
continued regression of the treated mesenteric lymph nodes
to 1.8 and 1.2 cm, respectively (Figure 2C).
He remained under close observation until a CT scan
in March 2020 demonstrated progression of disease within
the right adrenal gland and an upper abdominal mesenteric
lymph node that was not previously treated with RT. The
previously treated mesenteric lymph nodes continued to
decrease in size, measuring 1.3 and 1 cm, respectively.
Because of disease progression the patient was started on
weekly paclitaxel, with the potential for additional MRguided SBRT to be delivered to those sites pending review
of treatment response on upcoming restaging scans. A
timeline of his treatment course is summarized in Table 1.
Written informed consent was obtained from the patient
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for publication of this case report and any accompanying
images. A copy of the written consent is available for review
by the Editor-in-Chief of this journal.
Discussion
Radiation therapy (RT) for patients with distant metastasis
has historically been limited to low dose palliation of
symptoms such as pain or bleeding. However, dose
escalated RT for OM disease (typically defined as 1–5
metastatic lesions) has received substantial attention after
multiple randomized phase 2 trials demonstrated profound
improvements in long-term progression free survival (PFS)
and even potentially overall survival (OS) with the use of
SBRT and chemotherapy versus chemotherapy alone (3-5).
These trials included several different cancer types including
breast, lung, and colorectal. Most recently, a phase 2 trial
of OM prostate cancer patients showed that the SBRT arm
achieved significantly improved PFS and enhanced systemic
immune response compared to those randomized to
observation (6). There may be a benefit of SBRT for other
OM cancers including those of the bladder (7).
Despite increasing enthusiasm for SBRT in the
management of OM disease, questions remain about ideal

Ther Radiol Oncol 2020;4:20 | http://dx.doi.org/10.21037/tro-20-37

Page 4 of 7

Therapeutic Radiology and Oncology, 2020

A

B

C

Figure 2 Oligometastatic mesenteric lymph nodes (arrow) that had progressed on systemic therapy prior to magnetic resonance-guided
stereotactic body radiation therapy (A). Progressive radiographic response was observed 4 weeks (B) and 12 weeks (C) after ablation. The
patient had no significant toxicity despite small bowel (star) abutting the target lesions.

patient selection and the optimal therapeutic approach (8).
The aforementioned studies used a spectrum of radiation
dose fractionation schedules, some being ablative (e.g.,
BED10 ≥100 Gy) while others were non-ablative, largely
dependent on the anatomic location of the target lesion with
respect to normal organs. While lesions such as those in the
peripheral lung are excellent candidates to receive ablative
dose in 5 or fewer fractions others such as abdominal LNs
have historically not been because there is a considerable
risk of severe toxicity due to the proximity of radiosensitive
organs (e.g., bowel) (9). For example, Augugliaro et al.
published a retrospective analysis of 13 OM transitional cell
bladder cancer patients who received RT predominantly
to recurrent abdominal or pelvic LNs, most commonly
prescribed to 25 Gy in 5 fractions (BED10=37.5 Gy) (7).
This non-ablative dose did not result in serious toxicity
although restaging imaging after 3 months showed in-field
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progression among 38% of patients.
The emergence of MR-guided SBRT has begun to
transform the field of radiation oncology (10). Not only
does MRI offer superior soft tissue imaging over CT, thus
obviating the need for fiducial marker placement, but MRguided radiation therapy devices also provide continuous
intrafraction imaging of the tumor and surrounding normal
organs throughout treatment allowing for smaller set up
margins and ultimately target volumes. Additionally, while
modifying the treatment plan to account for interfraction
anatomic changes typically requires several days (when using
CT guidance offline adaptation), MR-guided devices can
create a new treatment plan within a few minutes based on
the current day’s anatomy (online adaptation) that facilitates
ablative treatment. MR-guided SBRT has resulted in
encouraging early clinical outcomes for OM disease and
inoperable primary disease (11-14). Dose escalation using
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Table 1 Timeline from events since original diagnosis of bladder cancer
Date

Event

January 2015

Diagnosed with invasive high-grade urothelial carcinoma of the bladder

February 2015

Radical cystectomy and prostatectomy, pelvic lymph node dissection (pT3bN2)

May 2017

Diagnosed with right adrenal gland metastasis

June 2017

Began gemcitabine/cisplatin

May 2018

Enlarging right adrenal gland metastasis and mesenteric lymph nodes (1.6 cm, 1.2 cm)
Discontinued gemcitabine/cisplatin and started atezolizumab

November 2018

Complete resolution of right adrenal metastasis
Stable mesenteric lymph nodes (3.1 cm, 1.6 cm)

June 2019

Enlarging mesenteric lymph nodes (5.9 cm, 1.9 cm)
Atezolizumab discontinued after 22 cycles

August 2019

MR-guided SBRT (50 Gy in 5 fractions) delivered to mesenteric lymph nodes

September 2019

Decreasing size of mesenteric lymph nodes (2.3 cm, 1.2 cm)

November 2019

Decreasing size of mesenteric lymph nodes (1.8 cm, 1.2 cm)

March 2020

Decreasing size of mesenteric lymph nodes (1.3 cm, 1.0 cm)
Progression in right adrenal gland and upper abdominal mesenteric lymph node
Began weekly paclitaxel

MR-guided SBRT is expected to improve outcomes far
beyond what is achievable using CT guidance, which is
especially relevant for patients with OM disease who may
achieve long-term survival with aggressive management (15).
Several logistical considerations are pertinent for patients
to be treated with an MR-LINAC. First, it must be verified
that there is no physical contraindication for having an
MRI scan due to implanted metallic objects or devices (i.e.,
prosthetic device, pacemaker). Second, patients must be able
to tolerate lying in the bore of the MR-LINAC, which is
more confined than a traditional LINAC. In our experience
this has not been a major limitation for claustrophobic
patients with the use of anxiolytic medication. Third, our
MR-LINAC requires that a breath hold volumetric scan
be performed for simulation and prior to each delivered
fraction; this scan is ideally done over 25 seconds to
achieve the highest image quality although can be done
in 17 seconds if needed. We have not had a patient who
was unable to tolerate at least the 17 second breath hold
scan. Lastly, while we typically treat patients with thoracic
or abdominal tumors in mid-inspiration breath hold to
improve duty cycle efficiency, treatment in free breathing
may be considered although the treatment time likely will
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increase.
Our patient had a remarkable response to MR-guided
SBRT without having significant adverse effects. Despite his
OM disease, his prognosis appears to be relatively favorable
given that he was originally diagnosed with bladder cancer
over 5 years ago, has not had widespread dissemination of
his cancer, and now has achieved a remarkable response to
SBRT. His case is notable because the delivery of ablative
radiation therapy to mesenteric lymph nodes has not
before been reported, to the best of our knowledge. Using
MR guidance we were able to safely prescribe 50 Gy in
5 fractions (BED10 =100 Gy), which is significantly higher
than what would typically be prescribed using CT guidance
due to the tolerance of the small bowel (e.g., 25–35 Gy
in 5 fractions; BED10 =37.5–59.5 Gy). From the patient’s
perspective, receiving MR-guided SBRT was a positive
experience since it was able to not only achieve tumor
reduction despite progression on prior systemic therapies,
but also offer him hope that he could still continue
effectively fighting his disease. He is optimistic that his
disease will remain controlled with chemotherapy and
that he potentially might receive additional SBRT to any
remaining sites of disease.
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The role of SBRT in the paradigm of OM management
will almost certainly expand moving forward based on
encouraging initial prospective data and the results of trials
currently in progress that are expected to show a benefit for
a wider array of cancer types. In that context, there will also
likely be an increasing indication for daily MRI guidance as
a means to optimize the therapeutic ratio of SBRT. Given
that there is not yet extensive follow up using ablative
dose with MR guidance, additional evaluation is needed
to better understand long-term safety and efficacy from
aggressive dosing regimens such as the one used for this
patient. As such, a prospective trial is under development
at our institution to evaluate outcomes of ablative MRguided SBRT delivered with online adaptive replanning for
patients with OM disease.
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